PSA Response to Neoadjuvant Androgen Deprivation Therapy Is a Strong Independent Predictor of Survival in High-Risk Prostate Cancer in the Dose-Escalated Radiation Therapy Era

International Journal of Radiation Oncology Biology Physics

Volumn 85, Issue 1, 2013, Pages

  McGuire, Sean E ^a,b   Lee, Andrew K ^a   Cerne, Jasmina Z ^b   Munsell, Mark F ^c   Levy, Lawrence B ^a   Kudchadker, Rajat J ^c   Choi, Seungtaek L ^a   Nguyen, Quynh N ^a   Hoffman, Karen E ^a   Pugh, Thomas J ^a   Frank, Steven J ^a   Corn, Paul G ^c   Logothetis, Christopher J ^c   Kuban, Deborah A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN DEPRIVATION THERAPY; BIOCHEMICAL RESPONSE; CLINICAL TRIAL; DISTANT METASTASIS; FAILURE-FREE SURVIVAL; INDEPENDENT PREDICTORS; MULTI VARIATE ANALYSIS; OVERALL SURVIVAL; PRE-TREATMENT; PROSTATE CANCERS; PROSTATE SPECIFIC ANTIGEN;

MULTIVARIANT ANALYSIS; PATIENT MONITORING; RADIOTHERAPY;

DISEASES;

ANDROGEN RECEPTOR ANTAGONIST; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; DISTANT METASTASIS; DRUG RESPONSE; FAILURE FREE SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE;

AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANDROGEN ANTAGONISTS; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 84871382961     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2012.08.036     Document Type: Article

References (21)

1. M.V. Pilepich, K. Winter, and M.J. John Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiation therapy in locally advanced carcinoma of the prostate Int J Radiat Oncol Biol Phys 50 2001 1243 1252 (Pubitemid 32727802)
2. M. Bolla, L. Collette, and L. Blank Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial Lancet 360 2002 103 108 (Pubitemid 34786197)
3. G.E. Hanks, T.F. Pajak, and A. Porter Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group protocol 92-02 J Clin Oncol 21 2003 3972 3978 (Pubitemid 46606211)
4. A.V. D'Amico, J. Manola, and M. Loffredo 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial JAMA 292 2004 821 827 (Pubitemid 39079668)
5. M.V. Pilepich, K. Winter, and C.A. Lawton Androgen suppression adjuvant to radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31 Int J Radiat Oncol Biol Phys 61 2005 1285 1290 (Pubitemid 40470408)
6. D.P. Dearnaley, M.R. Sydes, and J.D. Graham Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomized controlled trial Lancet Oncol 8 2007 475 487 (Pubitemid 46805903)
7. A.L. Zietman, K. Bae, and J.D. Slater Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/American college of radiology 95-09 J Clin Oncol 28 2010 1106 1111
8. N.L. Keating, A.J. O'Malley, and M.R. Smith Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer J Clin Oncol 24 2006 4448 4456 (Pubitemid 46630983)
9. J. Crook, C. Ludgate, and S. Malone Final report of multicenter Canadian phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer Int J Radiat Oncol Biol Phys 73 2009 327 333
10. A. Alexander, J. Crook, and S. Jones Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? An analysis of the 3- versus 8-month randomized trial Int J Radiat Oncol Biol Phys 76 2010 23 30
11. M.J. Zelefsky, O. Lyass, and Z. Fuks Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy J Clin Oncol 16 1998 3380 3385 (Pubitemid 28481636)
12. C. Ludgate, D.C. Bishop, and H. Pai Neoadjuvant hormone therapy and external-beam radiation for localized high-risk prostate cancer: the importance of PSA nadir before radiation Int J Radiat Oncol Biol Phys 62 2005 1309 1315 (Pubitemid 40982048)
13. D.M. Mitchell, J. McAleese, and R.M. Park Failure to achieve a PSA level ≤1 ng/ml after neoadjuvant LHRHa therapy predicts for lower biochemical control rate and overall survival in localized prostate cancer treated with radiotherapy Int J Radiat Oncol Biol Phys 69 2007 1467 1471 (Pubitemid 350116398)
14. J.J. Heymann, M.C. Benson, and K.M. O'Toole Phase II study of neoadjuvant androgen deprivation followed by external-beam radiotherapy with 9 months of androgen deprivation for intermediate- to high-risk localized prostate cancer J Clin Oncol 25 2007 77 84 (Pubitemid 350003054)
15. A.V. D'Amico, R. Whittington, and S.B. Malkowicz Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer JAMA 280 1998 969 974 (Pubitemid 28445094)
16. B.A. Williams, J.N. Mandrekar, and S.J. Mandrekar Finding optimal cut points for continuous covariates with binary and time-to-event outcomes Technical Report Series no. 79, Department of Health Sciences Research, Mayo Clinic 2006 Mayo Clinic Rochester, MN
17. E. Marubini, and M.G. Valsecchi Analysing Survival Data from Clinical Trials and Observational Studies 1995 John Wiley & Sons Chichester, UK
18. J.B. Choudhury Nonparametric confidence interval estimation for competing risk analysis: application to contraceptive data Stat Med 21 2002 1129 1140
19. J.P. Fine, and R.J. Gray A proportional hazards model for the subdistribution of a competing risk J Am Stat Assoc 94 1999 496 509
20. A.L. Zietman, E.A. Prince, and B.M. Nakfoor Androgen deprivation and radiation therapy: Sequencing studies using the Shionogi in vivo tumor system Int J Radiat Oncol Biol Phys 38 1997 1067 1070 (Pubitemid 27353687)
21. J.E. Fowler, S.A. Bigler, and D.L. Renfroe Prostate specific antigen in black and white men after hormonal therapies for prostate cancer J Urol 158 1997 150 154 (Pubitemid 27251613)